Lazard Asset Management
FENC icon

Lazard Asset Management’s Fennec Pharmaceuticals FENC Stock Holding History

Lazard Asset Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,121
Closed -$101K – 1941
2025
Q4 		$101K Buy
+13,121
New +$108K ﹤0.01% 1745
2024
Q4 		– Sell
-1,362
Closed -$6K – 2361
2024
Q3 		$6K Sell
1,362
-378
-22% -$2.19K ﹤0.01% 2046
2024
Q2 		$10K Buy
+1,740
New +$14.5K ﹤0.01% 2044

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Lazard Asset Management's FENC Position: Q1 2026 in Review

Lazard Asset Management sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 13,121 shares — an estimated $101K sold.

Lazard Asset Management first reported a position in FENC in Q2 2024 and held it in 3 quarters. The position peaked at $101K in Q4 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Lazard Asset Management reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Lazard Asset Management sold 13,121 Fennec Pharmaceuticals shares in Q1 2026, an estimated $101K.
  • Lazard Asset Management first reported a position in Fennec Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Lazard Asset Management's Fennec Pharmaceuticals position peaked at $101K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.